重大新闻！日元跌势恐将延续：日本央行鸽派态度令市场失望

日元跌势恐将延续：日本央行鸽派态度令市场失望

北京时间2024年6月18日，日本央行结束了为期两天的货币政策会议，并决定维持现行的超低利率政策不变。然而，央行有关缩减购债规模的言论却较为模糊，未能满足市场预期，导致日元汇率应声下跌。

日央鸽派立场意外

市场此前普遍预期，日本央行将在本次会议上宣布缩减购债规模，以抑制不断攀升的通胀。然而，央行最终却选择维持现有政策，并表示将继续关注经济形势。央行行长植田和男在新闻发布会上表示，“目前日本经济尚未完全摆脱疫情影响，需要继续维持宽松的货币政策来支持经济复苏。”

市场反应强烈 日元承压

植田和男的鸽派言论令市场感到意外，投资者纷纷抛售日元，导致日元汇率快速下跌。截至纽约汇市收盘，美元兑日元汇率上涨0.75%，报158.19日元，创下34年新高。

**分析人士指出，日元汇率的持续下跌将对日本经济产生重大影响。**一方面，进口商品价格将上涨，加剧通胀压力；另一方面，出口企业竞争力将增强，有利于出口增长。

未来展望：日元走势仍不明朗

目前，市场对日本央行未来的货币政策走向仍存分歧。**一些分析人士认为，日本央行可能会在未来几个月内进一步缩减购债规模，以遏制通胀。**但也有分析人士认为，日本央行将继续维持宽松政策，以支持经济增长。

**日元汇率的未来走势将取决于日本经济的表现和美联储的货币政策。**如果日本经济能够快速复苏，并缩小与美国的利差，那么日元汇率可能会有所回升。但如果日本经济持续低迷，美联储继续加息，那么日元汇率则可能继续下跌。

需要注意的是，以上内容仅供参考，不构成任何投资建议。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.